LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission of Innovative Medical Devices in respect of Aortic Arch Stent Graft System (Fenestration) into Special Examination and Approval Procedure

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company obtained formal written notice from the National Medical Products Administration ("**NMPA**") confirming the admission of Aortic Arch Stent Graft System (Fenestration) (the "**Product**") into NMPA Special Examination and Approval Procedure for Innovative Medical Services (藥監局創新醫療器械特別審查程序) (the"**Procedure**") on 18 October 2022. The Product is the 15th product of the Company having obtained admission to the Procedure.

The Product consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System (Branch Stent for Fenestration), which applies to the treatment of aortic dissection lesion involving the aortic arch. Ankura™ Plus Aortic Arch Stent Graft (the "**Main Stent Graft** ") is used for endovascular repair of the aorta, using Futhrough™ Endovascular Needle System to pierce the Main Stent Graft, thereby forming a puncture point. A balloon will subsequently be used to expand the puncture point, and branch blood vessels will be rebuilt through CSkirt™ Aortic Arch Branch Stent Graft (Branch Stent for Fenestration) (the "**Branch Stent Graft**").

The Branch Stent Graft adopts an original double-layer design. The inner layer can ensure smooth blood flows in blood vessels. The outer skirt can increase the stability of connection between the Main Stent Graft and the Branch Stent Graft, and can effectively block the gap between the Main Stent Graft. Additionally, the Branch Stent Graft possesses excellent adhesive ability, which can effectively reduce the occurrence of endoleak, improve the success rate of operation, and rebuild the branch of aortic arch according to different pathological conditions of the patients.

The Group possesses independent intellectual property rights to the Product. It is expected to provide a complete, safe and effective endovascular repair solution for the treatment of aortic dissection lesion involving the aortic arch, which is completely interventional with the expected benefits of causing less trauma, being simpler to operate and easier to acclimatize. At present, the pre-marketing clinical trials of the Product have entered the follow-up stage, and the initial follow-up results have been positive. In the future, the Company expects that there will be richer evidence-based medicine (EBM) evidence to further confirm the safety and effectiveness of the Product.

The Board believes that the admission of the Product into the Procedure will shorten the registration process of the Product, whereby expediting its launching process. It is expected that the launch of the Product will benefit patients suffering from aortic dissection lesion involving the aortic arch while enriching the Group's product portfolio and fostering the Group's development in medical devices.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman
and Chief Executive Officer

Hong Kong, 20 October 2022

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive directors; Mr. JIANG Feng being non-executive director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors.